Physician profile
Steven Nyquist
NPI 1306871868
$874.43
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.51 | 2019 | |
| Lundbeck LLC | $100.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $98.28 | 2019 | |
| Vanda Pharmaceuticals INC. | $74.31 | 2019 | |
| Bausch Health US, LLC | $66.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $63.32 | 2019 | |
| Neos Therapeutics, LP | $60.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.41 | 2019 | |
| Shire North American Group INC | $30.18 | 2019 | |
| Adlon Therapeutics L.P. | $17.64 | 2019 | |
| Neurocrine Biosciences, INC. | $15.37 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.97 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.81 | 2019 | |
| Allergan, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nyquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.